Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis By By Product Type (DTX-301, SEL-313, SHP-641, PRX-OTC), By End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Forecast 2024-2035
- PUBLISHED ON
- 24/03/2023
- NO OF PAGES
- 267
- CATEGORY
- Healthcare & Life Sciences
Ornithine Transcarbamylase (OTC) Deficiency is a rare genetic disorder that affects the urea cycle and can lead to toxic levels of ammonia in the blood. The Ornithine Transcarbamylase (OTC) Deficiency Treatment Market includes a range of therapies and interventions to manage the symptoms and complications of the condition.
The global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is expected to grow in the coming years, driven by increasing awareness and diagnosis of the condition, growing research and development efforts, and rising demand for effective treatments.
Currently, the market for OTC Deficiency Treatment includes several approaches, including dietary management, medication, and liver transplantation. Dietary management involves restricting protein intake and supplementing with essential amino acids and nitrogen scavengers to prevent the buildup of ammonia in the blood. Medications such as sodium benzoate and phenylacetate/phenylbutyrate can also help to reduce ammonia levels in the blood. Liver transplantation, which involves replacing the patient's diseased liver with a healthy liver from a donor, is considered a curative treatment for OTC Deficiency.
The market is segmented by treatment type, including dietary management, medications, and liver transplantation. Liver transplantation is currently the most effective treatment for OTC Deficiency, but it is also the most expensive and invasive. Medications are commonly used as a first-line treatment to reduce ammonia levels, while dietary management is used in conjunction with medication and other interventions to manage the condition long-term.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is currently the largest market, driven by a high prevalence of OTC Deficiency and the availability of advanced healthcare infrastructure. The Asia Pacific region is expected to experience significant growth in the coming years, driven by increasing awareness and diagnosis of the condition and rising demand for effective treatments.
Overall, the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is expected to grow in the coming years, driven by increasing awareness and diagnosis of the condition, growing research and development efforts, and rising demand for effective treatments.
Segment Overview
The Ornithine Transcarbamylase (OTC) Deficiency Treatment Market can be segmented based on the type of treatment, mode of administration, and end-user.
1. By type of treatment:
• Dietary management: It involves restricting protein intake and supplementing with essential amino acids and nitrogen scavengers to prevent the buildup of ammonia in the blood. This segment is expected to hold a significant market share due to the widespread use of dietary management in managing the condition.
• Medications: Medications such as sodium benzoate and phenylacetate/phenylbutyrate can help to reduce ammonia levels in the blood. This segment is expected to witness significant growth in the coming years, driven by the increasing availability of effective medications.
• Liver transplantation: Liver transplantation is considered a curative treatment for OTC Deficiency. This segment is expected to witness moderate growth due to its high cost and invasiveness.
2. By mode of administration:
• Oral: This is the most common mode of administration for medications and dietary supplements used in the treatment of OTC Deficiency.
• Intravenous: This mode of administration is typically used for medications that require rapid action to reduce ammonia levels.
3. By end-user:
• Hospitals: Hospitals are the primary end-users of OTC Deficiency Treatment, where patients can receive comprehensive care and treatment for the condition.
• Specialty Clinics: Specialty clinics that focus on the treatment of genetic disorders are also expected to witness significant growth in the coming years.
Geographically, the market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Geography Overview
Geographically, the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
1. North America: The North American market is expected to be the largest market for OTC Deficiency Treatment due to the high prevalence of the condition in the region. The United States is expected to account for the majority of the market share in this region.
2. Europe: The European market is expected to be driven by increasing awareness and diagnosis of the condition, as well as the presence of advanced healthcare infrastructure. The United Kingdom, Germany, and France are expected to be the largest markets in this region.
3. Asia Pacific: The Asia Pacific market is expected to experience significant growth in the coming years, driven by increasing awareness and diagnosis of the condition and rising demand for effective treatments. China, Japan, and India are expected to be the largest markets in this region.
4. Latin America: The Latin America market is expected to be driven by the presence of a large patient pool and increasing investment in healthcare infrastructure. Brazil and Mexico are expected to be the largest markets in this region.
5. Middle East and Africa: The Middle East and Africa market is expected to be driven by increasing investment in healthcare infrastructure and rising awareness of the condition. Saudi Arabia and South Africa are expected to be the largest markets in this region.
Overall, the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is expected to grow in all regions, driven by increasing awareness and diagnosis of the condition and rising demand for effective treatments.
COVID Impact
The COVID-19 pandemic has had a significant impact on the healthcare industry, including the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market. The impact of the pandemic on the market has been mixed, with both positive and negative effects.
On the positive side, the pandemic has increased awareness of the importance of healthcare and the need for effective treatments, which has led to increased investment in the development of new treatments for OTC Deficiency. The pandemic has also led to an increase in telemedicine and virtual care options, which has made it easier for patients with OTC Deficiency to access care and treatment.
However, the pandemic has also had negative impacts on the market. The pandemic has led to disruptions in the supply chain and manufacturing processes, which has affected the availability of treatments for OTC Deficiency. The pandemic has also led to a shift in healthcare priorities, with a focus on treating COVID-19 patients and reducing the spread of the virus, which has led to a decrease in attention and resources for other medical conditions, including OTC Deficiency.
Overall, the impact of the COVID-19 pandemic on the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market has been mixed, with both positive and negative effects. However, the market is expected to recover in the coming years, as the pandemic subsides and healthcare systems and economies stabilize.
Competitive Analysis
The Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is highly competitive, with several players operating in the market. Some of the major companies operating in the market include:
1. Horizon Therapeutics: Horizon Therapeutics is a biopharmaceutical company that develops and commercializes medicines for rare diseases, including OTC Deficiency. The company's product Ravicti (glycerol phenylbutyrate) is approved by the FDA for the treatment of OTC Deficiency.
2. Recordati Rare Diseases: Recordati Rare Diseases is a biopharmaceutical company that develops and commercializes medicines for rare diseases. The company's product Carbaglu (carglumic acid) is approved by the FDA for the treatment of OTC Deficiency.
3. Acer Therapeutics: Acer Therapeutics is a biopharmaceutical company that develops and commercializes therapies for rare diseases. The company's product Edsivo (celiprolol) is in clinical trials for the treatment of OTC Deficiency.
4. Ultragenyx Pharmaceutical: Ultragenyx Pharmaceutical is a biopharmaceutical company that develops and commercializes medicines for rare diseases. The company's product Crysvita (burosumab-twza) is approved by the FDA for the treatment of X-linked hypophosphatemia, which is sometimes associated with OTC Deficiency.
Historic Year: 2016-2022
Forecast: 2024-2035
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI